US2023364094A1PendingUtilityA1
Deuterated ruc-4
Est. expiryJun 19, 2038(~11.9 yrs left)· nominal 20-yr term from priority
Inventors:Yatindra Joshi
A61K 31/519A61K 38/12A61K 31/4365C07D 513/04A61K 38/482A61K 31/37A61K 31/702A61K 31/4465A61K 39/3955A61K 31/122A61K 31/616A61K 31/727C07B 2200/05A61K 45/06
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.
Claims
exact text as granted — not AI-modified1 - 59 . (canceled)
60 . A compound of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , and R 15 independently are hydrogen or deuterium;
provided that at least one of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , and R 15 is deuterium.
61 . The compound of claim 60 , of Formula (III):
or a pharmaceutically acceptable salt thereof.
62 . The compound of claim 61 , wherein at least one of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , and R 15 is deuterium.
63 . The compound of claim 60 , of Formula (IV):
or a pharmaceutically acceptable salt thereof.
64 . The compound of claim 63 , wherein at least one of R 1 and R 2 is deuterium.
65 . The compound of claim 63 , wherein at least one of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , and R 15 is deuterium.
66 . The compound of claim 60 , of Formula (V):
or a pharmaceutically acceptable salt thereof.
67 . The compound of claim 66 , wherein at least one of R 1 and R 2 is deuterium.
68 . The compound of claim 66 , wherein at least one of R 3 , R 4 , and R 6 is deuterium.
69 . The compound of claim 66 , wherein at least one of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , and R 15 is deuterium.
70 . The compound of claim 60 , of Formula (VI):
or a pharmaceutically acceptable salt thereof.
71 . The compound of claim 70 , wherein at least one of R 1 and R 2 is deuterium.
72 . The compound of claim 70 , wherein at least one of R 3 , R 4 , and R 6 is deuterium.
73 . A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
74 . A method for the treatment of a thrombotic disorder in a subject in need thereof, comprising administering to the subject a compound or pharmaceutically acceptable salt thereof of claim 60 .
75 . The method of claim 74 , wherein thrombotic disorder is myocardial infarction.
76 . The method of claim 74 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
77 . The method of claim 74 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
78 . The method of claim 74 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
79 . The method of claim 74 , wherein the compound is
or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2023364094A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.